Aurinia Pharmaceuticals Inc.
AUPH
$0.10
Change (1 day)
$10.05
Year High
$4.71
Year Low
Categories
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
P/E ratio for Aurinia Pharmaceuticals Inc. (AUPH)
P/E ratio as of 2023: -16.50
According to Aurinia Pharmaceuticals Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -16.50. At the end of 2022 the company had a P/E ratio of -5.67.
P/E ratio history for Aurinia Pharmaceuticals Inc. from 1998 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -16.50 |
| 2022 | -5.67 |
| 2021 | -16.35 |
| 2020 | -15.96 |
| 2019 | -15.22 |
| 2018 | -9.02 |
| 2017 | -5.27 |
| 2016 | -3.18 |
| 2015 | -4.27 |
| 2014 | -6.34 |
| 2013 | -9.72 |
| 2012 | -1.42 |
| 2011 | -5.60 |
| 2010 | -2.72 |
| 2009 | -1.23 |
| 2008 | -0.52 |
| 2007 | -0.24 |
| 2006 | -0.28 |
| 2005 | -0.21 |
| 2004 | -0.26 |
| 2003 | -0.37 |
| 2002 | -12.28 |
| 2001 | -0.54 |
| 2000 | -0.46 |
| 1999 | -1.73 |
| 1998 | -0.86 |